Should patients receive thrombophilia testing in the setting of a provoked VTE secondary to hormonal therapy/OCPs?
While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?
Answer from: at Academic Institution
Given that oral contraceptives are considered a provoking event (Ortel et al., PMID 33007077), ASH Choosing Wisely guidelines recommend against thrombophilia testing since the recommended duration of anticoagulation is only 3 months. (Hicks et al., PMID 24307720 & Hicks et al., PMID 25472968).
Comments
Medical Oncologist at Locum Tenens The danger is that many "providers" think that the...
Answer from: Medical Oncologist at Academic Institution
Thrombophilia associated with oral contraceptives is often the event that reveals an underlying thrombophilia, particularly Factor V Leiden. The most common population are young women who will be facing future potential thrombophilic risk, particularly pregnancy. It is more an issue for the future r...
The danger is that many "providers" think that the...